

# Rob J Vandebriel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1983874/publications.pdf>

Version: 2024-02-01

118  
papers

5,092  
citations

109137

35  
h-index

95083

68  
g-index

126  
all docs

126  
docs citations

126  
times ranked

7044  
citing authors

#	ARTICLE	IF	CITATIONS
1	Distribution, Elimination, and Toxicity of Silver Nanoparticles and Silver Ions in Rats after 28-Day Oral Exposure. <i>ACS Nano</i> , 2012, 6, 7427-7442.	7.3	624
2	A review of mammalian toxicity of ZnO nanoparticles. <i>Nanotechnology, Science and Applications</i> , 2012, 5, 61.	4.6	406
3	Allergic contact dermatitis: epidemiology, molecular mechanisms, in vitro methods and regulatory aspects. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 763-781.	2.4	286
4	Systemic and immunotoxicity of silver nanoparticles in an intravenous 28 days repeated dose toxicity study in rats. <i>Biomaterials</i> , 2013, 34, 8333-8343.	5.7	239
5	Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2016, 33, 272-321.	0.9	214
6	Sub-chronic toxicity study in rats orally exposed to nanostructured silica. <i>Particle and Fibre Toxicology</i> , 2014, 11, 8.	2.8	164
7	Risk assessment of titanium dioxide nanoparticles via oral exposure, including toxicokinetic considerations. <i>Nanotoxicology</i> , 2016, 10, 1515-1525.	1.6	119
8	Vaccine-induced antibody responses as parameters of the influence of endogenous and environmental factors.. <i>Environmental Health Perspectives</i> , 2001, 109, 757-764.	2.8	118
9	UVB exposure-induced systemic modulation of Th1 and Th2-mediated immune responses. <i>Immunology</i> , 1999, 97, 506-514.	2.0	110
10	Towards a nanospecific approach for risk assessment. <i>Regulatory Toxicology and Pharmacology</i> , 2016, 80, 46-59.	1.3	109
11	State of the art in non-animal approaches for skin sensitization testing: from individual test methods towards testing strategies. <i>Archives of Toxicology</i> , 2016, 90, 2861-2883.	1.9	95
12	Considerations for Safe Innovation: The Case of Graphene. <i>ACS Nano</i> , 2017, 11, 9574-9593.	7.3	94
13	Assessment of Preferential T-Helper 1 or T-Helper 2 Induction by Low Molecular Weight Compounds Using the Local Lymph Node Assay in Conjunction with RT-PCR and ELISA for Interferon- $\gamma$ and Interleukin-4. <i>Toxicology and Applied Pharmacology</i> , 2000, 162, 77-85.	1.3	88
14	The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2012, 29, 411-425.	0.9	87
15	A quantitative method for assessing the sensitizing potency of low molecular weight chemicals using a local lymph node assay: employment of a regression method that includes determination of the uncertainty margins. <i>Toxicology</i> , 2000, 146, 49-59.	2.0	81
16	Keratinocyte Gene Expression Profiles Discriminate Sensitizing and Irritating Compounds. <i>Toxicological Sciences</i> , 2010, 117, 81-89.	1.4	73
17	Immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats. <i>Particle and Fibre Toxicology</i> , 2014, 11, 21.	2.8	71
18	Cytokine Production Induced by Low-Molecular-Weight Chemicals as a Function of the Stimulation Index in a Modified Local Lymph Node Assay: An Approach to Discriminate Contact Sensitizers from Respiratory Sensitizers. <i>Toxicology and Applied Pharmacology</i> , 2002, 184, 46-56.	1.3	70

#	ARTICLE	IF	CITATIONS
19	Non-animal sensitization testing: State-of-the-art. <i>Critical Reviews in Toxicology</i> , 2010, 40, 389-404.	1.9	69
20	Genetic Variation in the Response to Vaccination. <i>Public Health Genomics</i> , 2007, 10, 201-217.	0.6	65
21	Horizon scan of nanomedicinal products. <i>Nanomedicine</i> , 2015, 10, 1599-1608.	1.7	62
22	In Vitro Testing for Direct Immunotoxicity: State of the Art. <i>Methods in Molecular Biology</i> , 2010, 598, 401-423.	0.4	61
23	Toxicogenomics of subchronic hexachlorobenzene exposure in Brown Norway rats.. <i>Environmental Health Perspectives</i> , 2004, 112, 782-791.	2.8	60
24	Assessment of potency of allergenic activity of low molecular weight compounds based on IL-1 $\beta$ and IL-18 production by a murine and human keratinocyte cell line. <i>Toxicology</i> , 2005, 210, 95-109.	2.0	58
25	An European inter-laboratory validation of alternative endpoints of the murine local lymph node assay: First round. <i>Toxicology</i> , 2005, 212, 60-68.	2.0	54
26	The Use of In Vitro Systems for Evaluating Immunotoxicity: The Report and Recommendations of an ECVAM Workshop. <i>Journal of Immunotoxicology</i> , 2005, 2, 61-83.	0.9	53
27	A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirements. <i>International Journal of Nanomedicine</i> , 2016, 11, 2935.	3.3	53
28	Use of statins is associated with an increased risk of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 648-654.	0.5	51
29	In vitro immunotoxicity of bis(tri-n-butyltin)oxide (TBTO) studied by toxicogenomics. <i>Toxicology</i> , 2007, 237, 35-48.	2.0	50
30	Ranking of Allergenic Potency of Rubber Chemicals in a Modified Local Lymph Node Assay. <i>Toxicological Sciences</i> , 2002, 66, 226-232.	1.4	46
31	An European inter-laboratory validation of alternative endpoints of the murine local lymph node assay. <i>Toxicology</i> , 2005, 212, 69-79.	2.0	46
32	Nanomedicinal products: a survey on specific toxicity and side effects. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 6107-6129.	3.3	46
33	In vitro assessment of sensitizing activity of low molecular weight compounds. <i>Toxicology and Applied Pharmacology</i> , 2005, 207, 142-148.	1.3	41
34	Host Genetics of <i>Bordetella pertussis</i> Infection in Mice: Significance of Toll-Like Receptor 4 in Genetic Susceptibility and Pathobiology. <i>Infection and Immunity</i> , 2006, 74, 2596-2605.	1.0	40
35	The crystal structure of titanium dioxide nanoparticles influences immune activity in vitro and in vivo. <i>Particle and Fibre Toxicology</i> , 2018, 15, 9.	2.8	40
36	The role of Toll-like receptor-4 in pertussis vaccine-induced immunity. <i>BMC Immunology</i> , 2008, 9, 21.	0.9	38

#	ARTICLE	IF	CITATIONS
37	Effects of in Vivo Exposure to Bis(tri-n-butyltin)oxide, Hexachlorobenzene, and Benzo(a)pyrene on Cytokine (Receptor) mRNA Levels in Cultured Rat Splenocytes and on IL-2 Receptor Protein Levels. <i>Toxicology and Applied Pharmacology</i> , 1998, 148, 126-136.	1.3	37
38	Toxicogenomics in the assessment of immunotoxicity. <i>Methods</i> , 2007, 41, 132-141.	1.9	36
39	Lipopolysaccharide Analogs Improve Efficacy of Acellular Pertussis Vaccine and Reduce Type I Hypersensitivity in Mice. <i>Vaccine Journal</i> , 2007, 14, 821-829.	3.2	35
40	Comparison of dose-responses of contact allergens using the guinea pig maximization test and the local lymph node assay. <i>Toxicology</i> , 2001, 167, 207-215.	2.0	34
41	Determination of the sensitising activity of the rubber contact sensitizers TMTD, ZDMC, MBT and DEA in a modified local lymph node assay and the effect of sodium dodecyl sulfate pretreatment on local lymph node responses. <i>Toxicology</i> , 2002, 176, 123-134.	2.0	34
42	Optimization of an air-liquid interface in vitro cell co-culture model to estimate the hazard of aerosol exposures. <i>Journal of Aerosol Science</i> , 2021, 153, 105703.	1.8	32
43	Association of <i>Bordetella pertussis</i> with host immune cells in the mouse lung. <i>Microbial Pathogenesis</i> , 2003, 35, 19-29.	1.3	31
44	In vitro exposure effects of cyclosporin A and bis(tri-n-butyltin)oxide on lymphocyte proliferation, cytokine (receptor) mRNA expression, and cell surface marker expression in rat thymocytes and splenocytes. <i>Toxicology</i> , 1999, 135, 49-66.	2.0	30
45	Impact of exposure duration by low molecular weight compounds on interferon- $\beta$ and interleukin-4 mRNA expression and production in the draining lymph nodes of mice. <i>Toxicology</i> , 2003, 188, 1-13.	2.0	29
46	Mechanism of Action of $\text{TiO}_2$ : Recommendations to Reduce Uncertainties Related to Carcinogenic Potential. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 203-223.	4.2	29
47	Association Between Statin Use and Lupus-Like Syndrome Using Spontaneous Reports. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 373-381.	1.6	28
48	Statin-Associated Polymyalgia Rheumatica. An Analysis Using WHO Global Individual Case Safety Database: A Case/Non-Case Approach. <i>PLoS ONE</i> , 2012, 7, e41289.	1.1	27
49	Strategies for the optimisation of in vivo experiments in accordance with the 3Rs philosophy. <i>Regulatory Toxicology and Pharmacology</i> , 2012, 63, 140-154.	1.3	27
50	Immunotoxicology: A brief history, current status and strategies for future immunotoxicity assessment. <i>Current Opinion in Toxicology</i> , 2017, 5, 55-59.	2.6	27
51	Multi-omics approaches confirm metal ions mediate the main toxicological pathways of metal-bearing nanoparticles in lung epithelial A549 cells. <i>Environmental Science: Nano</i> , 2018, 5, 1506-1517.	2.2	27
52	A methodology for developing key events to advance nanomaterial-relevant adverse outcome pathways to inform risk assessment. <i>Nanotoxicology</i> , 2021, 15, 289-310.	1.6	24
53	An Air-liquid Interface Bronchial Epithelial Model for Realistic, Repeated Inhalation Exposure to Airborne Particles for Toxicity Testing. <i>Journal of Visualized Experiments</i> , 2020, , .	0.2	24
54	Detection of immunotoxicity using T-cell based cytokine reporter cell lines (Cell Chip?). <i>Toxicology</i> , 2005, 206, 257-272.	2.0	23

#	ARTICLE	IF	CITATIONS
55	A practical approach to assess inhalation toxicity of metal oxide nanoparticles in vitro. <i>Journal of Applied Toxicology</i> , 2018, 38, 160-171.	1.4	23
56	Altered cytokine (receptor) mRNA expression as a tool in immunotoxicology. <i>Toxicology</i> , 1998, 130, 43-67.	2.0	22
57	Risk assessment and immunotoxicology. <i>Toxicology Letters</i> , 1998, 102-103, 261-265.	0.4	22
58	Dendritic cell-based in vitro assays for vaccine immunogenicity. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1323-1325.	1.4	22
59	Environmental and lifestyle factors may act in concert to increase the prevalence of respiratory allergy including asthma. <i>Clinical and Experimental Allergy</i> , 1999, 29, 1303-1308.	1.4	21
60	Statins accelerate the onset of collagen type II-induced arthritis in mice. <i>Arthritis Research and Therapy</i> , 2012, 14, R90.	1.6	20
61	Development of the 'Cell Chip': a new in vitro alternative technique for immunotoxicity testing. <i>Toxicology</i> , 2005, 206, 245-256.	2.0	19
62	Toll-Like Receptor 4 Polymorphism Associated with the Response to Whole-Cell Pertussis Vaccination in Children from the KOALA Study. <i>Vaccine Journal</i> , 2007, 14, 1377-1380.	3.2	19
63	Lung response to <i>Bordetella pertussis</i> infection in mice identified by gene-expression profiling. <i>Immunogenetics</i> , 2007, 59, 555-564.	1.2	19
64	Production of specific macrophage-arming factor precedes cytotoxic T lymphocyte activity in vivo during tumor rejection. <i>Cancer Immunology, Immunotherapy</i> , 1989, 30, 28-33.	2.0	18
65	Variability of in vivo potency tests of Diphtheria, Tetanus and acellular Pertussis (DTaP) vaccines. <i>Vaccine</i> , 2021, 39, 2506-2516.	1.7	17
66	Drivers and barriers in the consistency approach for vaccine batch release testing: Report of an international workshop. <i>Biologicals</i> , 2017, 48, 1-5.	0.5	16
67	Effect of prolonged exposure to low antigen concentration for sensitization. <i>Toxicology</i> , 2003, 184, 23-30.	2.0	15
68	The effect of zirconium doping of cerium dioxide nanoparticles on pulmonary and cardiovascular toxicity and biodistribution in mice after inhalation. <i>Nanotoxicology</i> , 2017, 11, 1-15.	1.6	15
69	Interleukin-10 is an Unequivocal Th2 Parameter in the Rat, whereas Interleukin-4 is Not *. <i>Scandinavian Journal of Immunology</i> , 2000, 52, 519-524.	1.3	14
70	Consequences of the expression of lipopolysaccharide-modifying enzymes for the efficacy and reactogenicity of whole-cell pertussis vaccines. <i>Microbes and Infection</i> , 2007, 9, 1096-1103.	1.0	14
71	Comparison of the molecular topologies of stress-activated transcription factors HSF1, AP-1, NRF2, and NF- $\kappa$ B in their induction kinetics of HMOX1. <i>BioSystems</i> , 2014, 124, 75-85.	0.9	14
72	Pattern of risks of rheumatoid arthritis among patients using statins: A cohort study with the clinical practice research datalink. <i>PLoS ONE</i> , 2018, 13, e0193297.	1.1	14

#	ARTICLE	IF	CITATIONS
73	Respiratory sensitization: Advances in assessing the risk of respiratory inflammation and irritation. <i>Toxicology in Vitro</i> , 2011, 25, 1251-1258.	1.1	13
74	Pattern of risks of systemic lupus erythematosus among statin users: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1723-1730.	0.5	13
75	Sensitive method for endotoxin determination in nanomedicinal product samples. <i>Nanomedicine</i> , 2019, 14, 1231-1246.	1.7	13
76	Applicability of organ-on-chip systems in toxicology and pharmacology. <i>Critical Reviews in Toxicology</i> , 2021, 51, 540-554.	1.9	13
77	Supplementation of whole-cell pertussis vaccines with lipopolysaccharide analogs: Modification of vaccine-induced immune responses. <i>Vaccine</i> , 2008, 26, 899-906.	1.7	12
78	Response of MUTZ-3 dendritic cells to the different components of the Haemophilus influenzae type B conjugate vaccine: Towards an in vitro assay for vaccine immunogenicity. <i>Vaccine</i> , 2011, 29, 5114-5121.	1.7	12
79	In vitro innate immune cell based models to assess whole cell Bordetella pertussis vaccine quality: A proof of principle. <i>Biologicals</i> , 2015, 43, 100-109.	0.5	12
80	Immunotoxicity Testing of Nanomedicinal Products: Possible Pitfalls in Endotoxin Determination. <i>Current Bionanotechnology</i> , 2017, 2, 95-102.	0.6	12
81	Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis. <i>Vaccine</i> , 2007, 25, 2346-2360.	1.7	11
82	Nonclinical regulatory immunotoxicity testing of nanomedicinal products: Proposed strategy and possible pitfalls. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2020, 12, e1633.	3.3	11
83	The value of organs-on-chip for regulatory safety assessment. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2020, 37, 208-222.	0.9	11
84	Differences in the Induction of Macrophage Cytotoxicity by the Specific T Lymphocyte Factor, Specific Macrophage Arming Factor (SMAF), and the Lymphokine, Macrophage Arming Factor (SMAF), and the Lymphokine, Macrophage Activating Factor (MAF). <i>Immunobiology</i> , 1989, 179, 131-144.	0.8	9
85	Gene polymorphisms within the immune system that may underlie drug allergy. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2004, 369, 125-132.	1.4	9
86	Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 835-843.	0.9	9
87	Statin Use and Markers of Immunity in the Doetinchem Cohort Study. <i>PLoS ONE</i> , 2013, 8, e77587.	1.1	8
88	Livestock farm particulate matter enhances airway inflammation in mice with or without allergic airway disease. <i>World Allergy Organization Journal</i> , 2020, 13, 100114.	1.6	8
89	Identification of biomarkers to detect residual pertussis toxin using microarray analysis of dendritic cells. <i>Vaccine</i> , 2013, 31, 5223-5231.	1.7	6
90	Cytokine production induced by low-molecular-weight chemicals as a function of the stimulation index in a modified local lymph node assay: an approach to discriminate contact sensitizers from respiratory sensitizers. <i>Toxicology and Applied Pharmacology</i> , 2002, 184, 46-56.	1.3	6

#	ARTICLE	IF	CITATIONS
91	Comparative gene expression profiling in two congenic mouse strains following Bordetella pertussis infection. BMC Microbiology, 2007, 7, 88.	1.3	5
92	Toward a mechanism-based in vitro safety test for pertussis toxin. Human Vaccines and Immunotherapeutics, 2014, 10, 1391-1395.	1.4	5
93	Role of chemical composition and redox modification of poorly soluble nanomaterials on their ability to enhance allergic airway sensitisation in mice. Particle and Fibre Toxicology, 2019, 16, 39.	2.8	5
94	Overcoming scientific barriers in the transition from in vivo to non-animal batch testing of human and veterinary vaccines. Expert Review of Vaccines, 2021, 20, 1-13.	2.0	5
95	Evaluation of Adverse Effects of Resorbable Hyaluronic Acid Fillers: Determination of Macrophage Responses. International Journal of Molecular Sciences, 2022, 23, 7275.	1.8	5
96	Initial immunochemical characterization of specific macrophage-arming factor. Cancer Immunology, Immunotherapy, 1989, 30, 21-27.	2.0	4
97	[9] Methods in immunotoxicology. Methods in Neurosciences, 1995, , 151-169.	0.5	4
98	A helper T-cell epitope of the E7 protein of human papillomavirus type 16 in BALB/c mice. Virus Research, 1995, 37, 13-22.	1.1	3
99	Cytokine Production Induced by Low-Molecular-Weight Chemicals as a Function of the Stimulation Index in a Modified Local Lymph Node Assay: An Approach to Discriminate Contact Sensitizers from Respiratory Sensitizers. , 2002, 184, 46-46.		3
100	Physiologically based pharmacokinetic modeling of intravenously administered nanoformulated substances. Drug Delivery and Translational Research, 2022, 12, 2132-2144.	3.0	3
101	An inter-laboratory comparison of an NLRP3 inflammasome activation assay and dendritic cell maturation assay using a nanostructured lipid carrier and a polymeric nanomedicine, as exemplars. Drug Delivery and Translational Research, 2022, 12, 2225-2242.	3.0	3
102	Risk assessment of titanium dioxide nanoparticles via oral exposure, including toxicokinetic considerations. Toxicology Letters, 2017, 280, S236.	0.4	2
103	A next-generation sequencing based method for determining genetic stability in Clostridium tetani vaccine strains. Biologicals, 2020, 64, 10-14.	0.5	2
104	A Decision Support System for preclinical assessment of nanomaterials in medical products: the REFINE DSS. Drug Delivery and Translational Research, 2022, , 1.	3.0	2
105	Effects of a Diphtheria-Tetanus-Acellular Pertussis Vaccine on Immune Responses in Murine Local Lymph Node and Lung Allergy Models. Vaccine Journal, 2007, 14, 211-219.	3.2	1
106	Cytokine Measurement Tools for Immunotoxicology. Methods in Pharmacology and Toxicology, 2007, , 17-30.	0.1	1
107	Impact of Nanoparticles on Dendritic Cells. Molecular and Integrative Toxicology, 2020, , 73-82.	0.5	1
108	Regulation of Clostridium tetani Neurotoxin Expression by Culture Conditions. Toxins, 2022, 14, 31.	1.5	1

#	ARTICLE	IF	CITATIONS
109	Pathways Related to NLRP3 Inflammasome Activation Induced by Gold Nanorods. International Journal of Molecular Sciences, 2022, 23, 5763.	1.8	1
110	a proteinaceous particle from the wax moth, Galleria mellonella. Journal of Invertebrate Pathology, 1985, 45, 363-364.	1.5	0
111	Specific T-cell factor production and lymphocytes in the direct surroundings of a subcutaneous allogeneic tumor. Cellular Immunology, 1992, 144, 269-286.	1.4	0
112	Specific T-Cell Factors That Initiate Cellular Immune Responses Are Produced by CD4-, CD8-, VÎ²8-Lymphocytes and Are Present in Nude Mice. Cellular Immunology, 1994, 159, 1-14.	1.4	0
113	In vitro approaches to the assessment of immunotoxicity. Toxicology Letters, 2007, 172, S6-S7.	0.4	0
114	Toxicogenomics as a Tool to Assess Immunotoxicity. , 0, , 127-142.		0
115	Response to 'Statins accelerate the onset of collagen type II-induced arthritis in mice'-authors' reply. Arthritis Research and Therapy, 2013, 15, 403.	1.6	0
116	Shape-dependent impact of gold nanoparticles on differentiating human dendritic cells. Toxicology Letters, 2017, 280, S312-S313.	0.4	0
117	Nanomedicinal products and immunotoxicity assessment: an improved and integrated strategy. Toxicology Letters, 2018, 295, S39.	0.4	0
118	Airborne particulate matter from goat farm increases acute allergic airway responses in mice. Inhalation Toxicology, 2020, 32, 265-277.	0.8	0